Dolat Capital: Emami Delivers A Stellar Q2 Performance
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Emami Ltd.’s Q2 FY21 results came ahead of our estimates. Domestic business jumped 13%, while international business posted 11% revenue growth in Q2.
Ex-winter products (88% contribution) reported 28% growth was encouraging performance.
Kesh King and pain management range recorded highest ever quarterly sales during the quarter.
The company launched eight new products during the quarter. New product development contributes 4% of total revenues.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.